Physician Acceptance of the NeuTrace System for Cardiac Electroanatomic Mapping

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-07

Study Completion Date

2024-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The trial is a prospective, non-randomized, single-arm feasibility trial to evaluate physician acceptance of the NeuTrace System v1.0 for cardiac electroanatomic mapping.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

NCT06609174

Cardiomyopathy

COMPLETED NA

AI Powered Mapping Technology for Identifying Arrhythmias

NCT06939478

Arrhythmias, Cardiac

RECRUITING

Micra Transcatheter Pacing Study

NCT02004873

Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines

COMPLETED NA

The Fluoroless-CSP Trial Using Electroanatomic Mapping

NCT03903107

Sinus Node Dysfunction Heart Block AV LBBB +1 more

COMPLETED NA

Evaluation of a New Cardiac Pacemaker

NCT01700244

Atrial Fibrillation With 2 or 3° AV or Bifascicular Bundle Branch (BBB) Block Normal Sinus Rhythm With 2 or 3° AV or BBB Block Sinus Bradycardia With Infrequent Pauses or Unexplained Syncope With EP Findings

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Arrhythmias, or abnormal heart rhythms, are a major cause of morbidity and mortality worldwide. In patients with arrhythmias, electrophysiology (EP) studies are often performed to assess the electrical system of the heart. Since its introduction in the 1990s, electroanatomic mapping has become a cornerstone of EP studies. Electroanatomic mapping systems allow for non-fluoroscopic navigation of the heart and the creation of three-dimensional (3D) anatomic and electroanatomic maps. These maps facilitate diagnosing and treating arrhythmias.

The NeuTrace System is a cardiac EP mapping system that is intended to be used during catheter-based atrial and ventricular mapping procedures. The system is designed to acquire and analyze data points and use this information to display 3D anatomical and electroanatomic mapping of the human heart. The system is used with a compatible, marketed magnetic sensor-enabled catheter and compatible EP recording system to acquire the location information and local electrogram needed to create the cardiac maps. The purpose of the trial is to evaluate physician acceptance and feasibility of the NeuTrace System v1.0 for cardiac electroanatomic mapping.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arrhythmias, Cardiac Atrial Fibrillation Atrial Flutter

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective, non-randomized, single-arm trial

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Electroanatomic mapping with NeuTrace System

Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.

Group Type EXPERIMENTAL

Electroanatomic mapping with the NeuTrace System

Intervention Type DEVICE

Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electroanatomic mapping with the NeuTrace System

Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with standard indications for an electrophysiology study and/or catheter ablation per European Heart Rhythm Association/Heart Rhythm Society) guidelines and/or judgement of the investigator
* Age 18 to 80
* Signed Informed Consent Form

Exclusion Criteria

* Any cardiac surgery, myocardial infarction, percutaneous coronary intervention/percutaneous transluminal coronary angioplasty, or coronary artery stenting which occurred during the 90-day interval preceding the date that participant signed the Informed Consent Form
* Unstable angina
* NHYA class III or IV congestive heart failure and/or known left ventricular ejection fraction less than 45%
* Thrombocytosis, thrombocytopenia
* Contraindication to anticoagulation therapy
* Active systemic infection
* Cryoglobulinemia
* Known reversible causes of arrhythmia
* Any cerebral ischemic event (stroke or transient ischemic attacks) which occurred during the 180-day interval preceding the date the participant signed the Informed Consent Form, or any known unresolved complications from the previous stroke/transient ischemic attack
* Pregnancy
* Unwilling or unable to comply fully with study procedures

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No